Search Videos by Topic or Participant
Browse by Series:

Potential Targets in Muscle-Invasive Bladder Cancer

Insights From: Dean F. Bajorin, MD, MSKCC; Daniel P. Petrylak, MD, Yale;Evan Y. Yu, MD, Seattle Cancer Care
Published: Thursday, May 28, 2015
For High-Definition, Click

A genome sequencing study examined patients who received everolimus for muscle-invasive bladder. In this study, one patient who was positive for both the lytic protein, Tse1, and neurofibromin 2 (NF2) mutations was particularly sensitive to everolimus therapy, Dean F. Bajorin, MD, notes. Upon further review, it was found that other patients who had received some benefit all had the Tse1 mutation.

Other potentially actionable mutations under investigation include human epidermal growth factor receptor 2 (HER2) and fibroblast growth factor receptor 3 (FGFR3), says Bajorin. Evan Y. Yu, MD, notes that several vascular endothelial growth factor (VEGF) inhibitors, including bevacizumab, ramucirumab, and docetaxel, are being evaluated as second- and third-line treatments of bladder cancer.
Slider Left
Slider Right
For High-Definition, Click

A genome sequencing study examined patients who received everolimus for muscle-invasive bladder. In this study, one patient who was positive for both the lytic protein, Tse1, and neurofibromin 2 (NF2) mutations was particularly sensitive to everolimus therapy, Dean F. Bajorin, MD, notes. Upon further review, it was found that other patients who had received some benefit all had the Tse1 mutation.

Other potentially actionable mutations under investigation include human epidermal growth factor receptor 2 (HER2) and fibroblast growth factor receptor 3 (FGFR3), says Bajorin. Evan Y. Yu, MD, notes that several vascular endothelial growth factor (VEGF) inhibitors, including bevacizumab, ramucirumab, and docetaxel, are being evaluated as second- and third-line treatments of bladder cancer.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x